Role of the renin-angiotensin-aldosterone system and the glutathione S-transferase Mu, Pi and Theta gene polymorphisms in cardiotoxicity after anthracycline chemotherapy for breast carcinoma

International Journal of Biological Markers

Volumn 28, Issue 4, 2013, Pages

  Vivenza, Daniela ^a   Feola, Mauro ^b   Garrone, Ornella ^a   Monteverde, Martino ^a   Merlano, Marco ^a   Lo Nigro, Cristiana ^a  

^a S CROCE E CARLE HOSPITAL   (Italy)

^b Medical Oncology Unit   (Italy)

Author keywords

Anthracycline cardiotoxicity; Breast cancer; Gene polymorphism; Renin angiotensin aldosterone system (RAAS)

Indexed keywords

ADRENALIN; ALDOSTERONE; ALDOSTERONE SYNTHASE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSINOGEN; ANTHRACYCLINE; BRAIN NATRIURETIC PEPTIDE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE; EPIRUBICIN; FLUOROURACIL; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE MU; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE THETA; HEMOGLOBIN; NORADRENALIN; TROPONIN I; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CARDIOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPING TECHNIQUE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; MALE; POLYMERASE CHAIN REACTION; PREDICTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ANGIOTENSINOGEN; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FLUOROURACIL; GLUTATHIONE TRANSFERASE; HEART DISEASES; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RENIN-ANGIOTENSIN SYSTEM;

EID: 84890655949     PISSN: 03936155     EISSN: 17246008     Source Type: Journal    
DOI: 10.5301/jbm.5000041     Document Type: Article

References (46)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-717.
2. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1995; 332: 1738-43.
3. Von Hoff D, Layard M, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Inter Med 1979; 91: 710-7.
4. Praga C, Trave F, Petroccione A. Anthracycline-induced cardiotoxicity and its relevance in cancer treatment. In: Nimmo WS, Tucker GT (eds). Clinical Measurement in Drug Evaluation. Boca Raton, FL; CRC Press 1991; 131-42.
5. Abassi Z, Winaver J, Feuerstein GZ. The biochemical pharmacology of renin inhibitors: implications for translational medicine in hypertension, diabetic nephropathy and heart failure: expectations and reality. Biochem Pharmacol 2009; 78: 933-40.
6. Gard PR. Implications of the angiotensin converting enzyme gene insertion/deletion polymorphism in health and disease: a snapshot review. Int J Mol Epidemiol Genet 2010; 1: 145-57.
7. Gambaryan S, Butt E, Tas P, Smolenski A, Allolio B, Walter U. Regulation of aldosterone production from zona glomerulosa cells by ANG II and cAMP: evidence for PKAindependent activation of CaMK by cAMP. Am J Physiol Endocrinol Metab 2006; 290: 423-33.
8. Ruggenenti P, Cravedi P, Remuzzi G. The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol 2010; 6: 319-30.
9. Rosskopf D, Schürks M, Rimmbach C, Schäfers R. Genetics of arterial hypertension and hypotension. Naunyn Schmiedebergs Arch Pharmacol 2007; 374: 429-69.
10. Hahntow IN, Mairuhu G, van Valkengoed IG, Koopmans RP, Michel MC. Are "functionally related polymorphisms" of renin-angiotensin-aldosterone system gene polymorphisms associated with hypertension? BMC Cardiovasc Disord 2010; 2: 10-23.
11. Alvarez-Madrazo S, Connell JM, Freel EM. Role of genetic variation in regulation of aldosterone biosynthesis. Endocr Dev 2011; 20: 106-15.
12. White PC, Rainey WE. Polymorphisms in CYP11B genes and 11-hydroxylase activity (editorial). J Clin Endocrinol Metab 2005; 90: 1252-5.
13. Iqbal S, Lenz HJ. Targeted therapy and pharmacogenomic programs. Cancer 2003; 97: 2076-82.
14. Coles BF, Kadlubar FF. Detoxification of electrophilic compounds by glutathione S-transferase catalysis: determinants of individual response to chemical carcinogens and chemotherapeutic drugs? Biofactors 2003; 17: 115-30.
15. Townsend DM and Tew K. Cancer drugs, genetic variation and the glutathione drug resistance. Cancer Bull 2003; 3: 157-72.
16. McIlwain CC, Townsend DM, Tew K. Gluthatione S-transferase polymorphisms: cancer incidence and therapy. Oncogene 2006; 25: 1639-48.
17. Riddick DS, Lee C, Ramji S, et al. Cancer chemotherapy and drug metabolism. Drug Metab Dispos 2005; 33: 1083-96.
18. Feola M, Garrone O, Occelli M, et al. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. Int J Cardiol 2011; 148: 194-8.
19. Garrone O, Crosetto N, Lo Nigro C, et al. Prediction of anthracycline cardiotoxicity after chemotherapy by biomarkers kinetic analysis. Cardiovasc Toxicol 2012; 12: 135-42.
20. Sethi AA, Nordestgaard BG, Tybjaerg-Hansen A. Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease: a metaanalysis. Arterioscler Thromb Vasc Biol 2003; 23: 1269-75.
21. Sethi AA, Nordestgaard BG, Gronholdt ML, Steffensen R, Jensen G, Tybjaerg-Hansen A. Angiotensinogen single nucleotide polymorphisms, elevated blood pressure, and risk of cardiovascular disease. Hypertension 2003; 41: 1202-11.
22. Freitas AI, Mendonça I, Brión M, et al. RAS gene polymorphisms, classical risk factors and the advent of coronary artery disease in the Portuguese population. BMC Cardiovasc Disord 2008; 8: 15.
23. Niu T, Xu X, Rogus J, et al. Angiotensinogen gene and hypertension in Chinese. J Clin Invest 1998; 101: 188-94.
24. Bloem LJ, Foroud TM, Ambrosius WT, Hanna MP, Tewksbury DA, Pratt JH. Association of the angiotensinogen gene to serum angiotensinogen in blacks and whites. Hypertension 1997; 29: 1078-82.
25. Johnson AD, Newton-Cheh C, Chasman DI, et al. Association of hypertension drug target genes with blood pressure and hypertension in 86, 588 individuals. Hypertension 2011; 57: 903-10.
26. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-6.
27. Bonnardeaux A, Davies E, Jeunemaitre X, et al. Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 1994; 24: 63-9.
28. Srivastava K, Sundriyal R, Meena PC, Bathia J, Narag R, Saluja D. Association of angiotesin converting enzyme (Insertion/Deletion) gene polymorphism with essential hypertension in northern Indian subjects. Genet Test Mol Biomarkers 2012; 16: 174-7.
29. Ned RM, Yesupriva A, Imperatore G, et al. The ACE I/D polymorphism in US adults: limited evidence of association with hypertension-related traits and sex-specific effects by race/ethnicity. Am J Hypertens 2012; 25: 209-15.
30. Wang WY, Zee RY, Morris BJ. Association of angiotensin II type 1 receptor gene polymorphism with essential hypertension. Clin Genet 1997; 51: 31-4.
31. Zhang KX, Liu TB, Xu QX, Zhu DL, Huang W. Association of angiotensin II receptor type 1 gene single nucleotide polymorphism with Chinese essential hypertension complicated with coronary heart disease. Zhonghua Xin Xue Guan Bing Za Zhi 2005; 33: 720-803.
32. Matsubara M. Genetic determination of human essential hypertension. Tohoku J Exp Med 2000; 192: 19-33.
33. Martin MM, Buckenberger JA, Jiang J, et al. The human angiotensin II type 1 receptor +1166 A/C polymorphism attenuates microrna-155 binding. J Biol Chem 2007; 282: 24262-9.
34. Hannila-Handelberg T, Kontula KK, Paukku K, et al. Common genetic variations of the renin-angiotensin-aldosterone system and response to acute angiotensin I-converting enzyme inhibition in essential hypertension. J Hypertension 2010; 28: 771-9.
35. Sookoian S, Gianotti TF, Pirola CJ. Role of the C-344T aldosterone synthase gene variant in left ventricular mass and left ventricular structure-related phenotypes. Heart 2008; 94: 903-10.
36. Tamaki S, Iwai N, Tsujita Y, Kinoshita M. Genetic polymorphism of CYP11B2 gene and hypertension in Japanese. Hypertension 1999; 33: 266-70.
37. Brand E, Chatelain N, Mulatero P, et al. Structural analysis and evaluation of the aldosterone synthase gene in hypertension. Hypertension 1998; 32: 198-204.
38. Garnier A, Bendall JK, Fuchs S, et al. Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation 2004; 110: 1819-25.
39. Perrin CW, Rainey WE. Editorial: polymorphism in CTP11B genes and 11-hydroxylase activity. Journ Clin Endocr Metab 2005; 90: 1252-5.
40. Oliveira AL, Rodrigues FF, Santos RE, et al. GSTT1, GSTM1, and GSTP1 polymorphisms and chemotherapy response in locally advanced breast cancer. Genet Mol Res 2010; 9: 1045-53.
41. Lizard-Nacol S, Coudert B, Colosetti P, Riedinger JM, Fargeot P, Brunet-Lecomte P. Glutathione S-transferase M1 null genotype: lack of association with tumour characteristics and survival in advanced breast cancer. Breast Cancer Res 1999; 1: 81-7.
42. Saxena A, Dhillon VS, Raish M, et al. Detection and relevance of germline genetic polymorphisms in glutathione S-transferases (GSTs) in breast cancer patients from northern Indian population. Breast Cancer Res Treat 2009; 115: 537-43.
43. Kostrykina NA, Pechkovskii EV, Mishukova OV, et al. Studying the association of polymorphic variants of GSTM1 and GSTT1 genes with breast cancer in female residents of Altai Krai. Bull Exp Biol Med 2009; 148: 89-93.
44. Gor PP, Su HI, Gray RJ, et al. Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast Cancer Res 2010; 12: R26.
45. Ambrosone CB, Sweeney C, Coles BF, et al. Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Res 2001; 61: 7130-5.
46. Zhu H, Jia Z, Zhou K, et al. Cruciferousdithiolethionemediated coordinated induction of total cellular and mitochondrial antioxidants and phase 2 enzymes in human primary cardiomyocytes: cytoprotection against oxidative/electrophilic stress and doxorubicin toxicity. Exp Biol Med 2009; 234: 418-29.